Our company has received notification from the patent firm that the Korean Patent Certificate for “Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method” has been granted, under Application No. 10-2022-0140542.
The composition and administration method for upper respiratory tract drug delivery (OBM-B01), developed by Original BiomMdicals, has received notification from the Taiwan Food and Drug Administration (TFDA) approving the initiation of Phase I human clinical trials.
Our company has received notification from the patent firm that the European Patent Certificate for “Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method” has been granted, under Application EP22204330.9.
Our company has received notification from the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospital that our application for the project titled “First-in-Human Study of Inhalation of a Fixed-Ratio Combination of Vitamin B12 (Hydroxocobalamin, OHCbl) and Iron Chelator (Deferoxamine Mesylate, DFO) Using a Drug Nebulizer in Healthy Adults” has been approved.
Our company’s OBM-B01 cyanide compound drug project has been entrusted to OP NANOPHARMA Co., Ltd. for the development and manufacturing of the lyophilized formulation.
Extends drug half-life
Reduce the side effects of drug
Nanocomposite microcells + Metal controlled release
Scale-up and commercialization of the manufacturing process
High drug stability
Design of the particle size
I ron chelators and iron can be used together to regulate drug release time
Improved new drugs
Clinical shortcomings of modified drugs
Fast forensics / High success rate
Functional excipients
We specialize in the development of new drugs without new ingredients, focusing on new formulations, new dosages, and new indications in drug delivery systems to enhance efficacy and reduce side effects. By repurposing existing drugs, we shorten development time and save drugs that are at risk of failure. Our research and development process includes synthesis, purification, method development, formulation design, and safety testing. Clinical production is completed by cGMP-certified manufacturing facilities.
